CAR is a transmembrane protein that is expressed in various epithelial and endothelial cells. CAR mediates adenoviral infection, as well as adenovirus-mediated oncolysis of AxdAdB-3, an E1A/E1B double-restricted oncolytic adenovirus, in prostate cancer cells. This study further assessed the therapeutic efficacy of AxdAdB-3 with Arg-Gly-Asp (RGD)-fiber modification (AxdAdB3-F/RGD), which enables integrin-dependent infection, in prostate cancer. Susceptibility of prostate cancer cells LNCaP, PC3, and DU145 to adenovirus infection was associated with CAR expression. All of the prostate cancer cell lines expressed integrin αvβ3 and αvβ5. AxdAdB-3 was more cytopathic in CAR-positive prostate cancer cells than in CAR-negative cells, whereas AxdAdB3-F/RGD caused potent oncolysis in both CAR-positive and CAR-negative prostate cancer cells. In contrast, AxdAdB3-F/RGD was not cytopathic against normal prostate epithelial cells, RWPE-1. Intratumoral injection of AxdAdB3-F/RGD into CAR-negative prostate cancer cell xenografts in nude mice inhibited tumor growth. The current study demonstrates that E1A/E1B double-restricted oncolytic adenovirus with an RGD-fiber modification enhances infection efficiency and anti-tumor activity in CAR-deficient prostate cancer cells, while sparing normal cells. Future studies will evaluate the therapeutic potential of AxdAdB3-F/RGD in prostate cancer.
Citation: Shen Y-H, Yang F, Wang H, Cai Z-J, Xu Y-P, Zhao A, et al. (2016) Arg-Gly-Asp (RGD)-Modified E1A/E1B Double Mutant Adenovirus Enhances Antitumor Activity in Prostate Cancer Cells In Vitro and in Mice. PLoS ONE 11(1): e0147173. doi:10.1371/journal.pone.0147173
Editor: Ilya Ulasov, Swedish Neuroscience Institute, UNITED STATES
Received: May 10, 2015; Accepted: December 30, 2015; Published: January 22, 2016
Copyright: © 2016 Shen et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: All relevant data are within the paper.
Funding: This study was supported in part by a grant from Natural Science Foundation of Zhejiang Province, China (#LY12H16031) and from the Health Bureau of Zhejiang Province, China (#2012KYA025).
Competing interests: The authors have declared that no competing interests exist.
Prostate cancer is the most commonly occurring malignancy in the world, especially in Western countries. It is estimated that prostate cancer will cause 220,800 new cases and 27,540 cancer-related deaths in the US in 2015. In China, prostate cancer incidence has been rapidly increasing in the past decades, and more than 70% of prostate cancer patients have advanced or metastatic disease. To date, hormone therapy is still the most useful therapy for patients with prostate cancer, but it is administered for a limited a period of time and almost all prostate cancer patients who receive androgen ablation ultimately progress to androgen refractory disease, known as castration-resistant prostate cancer (CRPC). Docetaxel-based chemotherapy is often used to treat patients with CRPC, but progression-free survival only lasts six months. Although the novel androgen receptor inhibitor (Enzalutamide) and cytochrome p450, family 17, subfamily A polypeptide (CYP17) inhibitor (Abiraterone) have been reported to more effectively treat CRPC patients, such treatment can only improve survival for a few months.[5, 6] Therefore, novel and more effective treatment strategies are urgently needed to improve prostate cancer prognosis.
Previous studies showed that an oncolytic adenovirus was able to selectively replicate and kill cancer cells while sparing normal cells. This oncolytic viral therapy could be clinically promising for treating human cancers, including prostate cancer.[7–9] Our previous study demonstrated that an E1A/E1B double mutant oncolytic adenovirus, AxdAdB-3, had antitumor activity in an orthotopic, prostate cancer SCID (severe combined immunodeficiency) mouse model. However, AxdAdB-3 showed insufficient cytopathic effects in some prostate cancer cell lines that expressed low levels of coxsackie virus adenovirus receptor (CAR). CAR is a transmembrane protein that is expressed in various epithelial and endothelial cells and functions to mediate adenoviral infection. Cancer cells with decreased CAR expression have been reported to be resistant to viral infection and adenovirus-mediated gene therapy. In prostate cancer, CAR expression is frequently absent,[12, 13] which could limit use of adenovirus-delivered gene therapy. A previous study demonstrated that insertion of the Arg-Gly-Asp (RGD) peptide into the HI loop of the fiber knob domain enhanced the adenovirus mediated gene transduction in CAR-negative cells through the binding of the RGD peptide to integrins on the target cells. Thus, in this study, we evaluated the therapeutic efficacy of the E1A/E1B double mutant oncolytic adenovirus, AxdAdB-3, with Arg-Gly-Asp (RGD)-fiber modification (AxdAdB3-F/RGD) in prostate cancer in vitro and in nude mice.
Materials and Methods
Cell lines and culture
Human androgen-dependent prostate cancer cell line LNCaP (metastasis to the lymph node), human androgen-independent prostate cancer cell lines PC3 (metastasis to the bone) and DU145 (metastasis to the brain), and normal adult prostate epithelial cells infected with a single copy of human papilloma virus 18 (named RWPE-1) were obtained from American Type Culture Collection (ATCC) (Manassas, VA, USA). LNCaP cells have wild type p53 and p16 expression;[15, 16] PC3 cells have mutated p53 but methylated wild type p16;[15, 16] and DU-145 cells have both mutated p53and p16.[15, 16] Human embryonic kidney 293 (HEK-293) cells were obtained from the Cell Bank of Chinese Academy of Sciences (Shanghai, China). Cell lines were maintained in Roswell Park Memorial Institute or Eagle’s minimal essential medium (for HEK293) supplemented with 10% fetal bovine serum, 100 IU/ml penicillin, and 100 μg/ml streptomycin in humidified 5% CO2 atmosphere at 37°C. RWPE-1 were maintained in K-SFM complete medium (Cell Systems, Kirkland, WA, USA) and then arrested in K-SFM without serum growth factor before viral infection.
Recombinant adenovirus and cell infection
AxCAZ3-F/RGD  and AxCAlacZ  are E1 deleted replication-defective adenovirus vectors expressing Escherichia coli lacZ gene under the control of the CAG promoter with or without an RGD peptide in the HI loop of the fiber knob domain. AxdAdB-3 has a mutant replication-competent Ad5 containing the SXGXE (STGHE) mutation instead of the LXCXE (LTCHE) Rb-binding motif in E1A and deletion of E1B55 KD . To construct AxdAdB3-F/RGD using pWEAxKM-F/RGD, we cloned the RGD-4C amino acids in the HI loop of the fiber knob domain between amino acid residues 546 and 547 with an E3 deletion. The amino acid sequences of the RGD-mutation were T 546 CDCRGDCFCP 547. AxdAdB3-F/RGD was generated by co-transfecting HEK293 cells with pWEAxKM-F/RGD cosmid DNA, which had been digested with ClaI and PacI, together with the EcoRI- and AseI-digested DNA-TPC (terminal protein complex) of AxdAdB3 . The viral vectors were provided by the RIKEN Gene Bank (Tsukuba, Japan) and transfected into HEK293 cells to produce adenoviruses and the viral titer was determined by a standard plaque assay.
For infection, cells were seeded onto a 6-well plate and grown overnight. On the next day, cells were infected with AxCAlacZ or AxCAZ3-F/RGD at a multiplicity of infection (MOI) of 100 for 24 h. Expression of adenoviral hexon protein in the infected cells was determined by Western blot analysis. Meanwhile, cells were infected with AxCAlacZ or AxCAZ3-F/RGD adenoviruses at a MOI of 100 for 24 h and levels of adenoviral hexon protein in infected cells were then assessed using flow cytometry (described in the following section) with a mouse monoclonal anti-hexon antibody (MAB805, Chemicon International, Temecula, CA).
Protein extraction and Western blot
Cells were lysed in 100 μl lysis buffer and protein concentration was measured by the BCA method. Next, equal amounts of protein samples in the supernatant were separated using sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) in a 12% SDS-PAGE gel and then transferred onto a polyvinylidene difluoride membrane (Millipore, Billerica, MA, USA). The membrane was then incubated with a mouse monoclonal anti-hexon antibody (MAB805, Chemicon International, Temecula, CA, USA) and subsequently incubated with an anti-mouse IgG antibody for 1 h followed by enhanced chemiluminescence (ECL; Cell Signaling Technology, MI, CA, USA). The membrane was then exposed to x-ray films and scanned for quantitation using Image J Software (National Institute of Heath, Bethesda, MD, USA).
Flow cytometry to determine expression of CAR and integrin levels in cells
Cells were seeded onto a 6-well plate and grown overnight. To detect expression of CAR and integrin αvβ3 and αvβ5, the cells were detached using an enzyme-free dissociation solution and then incubated with a mouse monoclonal anti-human CAR antibody (Upstate Biotechnology, Lake Placid, NY, USA), a mouse monoclonal anti-human integrin αvβ3 antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA), or a mouse monoclonal anti-human integrin αvβ5 antibody (R&D Systems, Inc., Minneapolis, MN, USA), all at a dilution of 1:100 for 1 h on ice. Next, the cells were washed three times with phosphate buffered saline (PBS), and then further incubated for 30 min with a secondary fluorescein isothiocyanate-conjugated antibody. Following the washes, the cells were immediately analyzed by a flow cytometer (Becton Dickinson, San Jose, CA, USA).
Cell viability cell counting kit-8 (CCK-8) assay
Cells (3 x 103 per well) were seeded onto 96-well plates and infected with AxCAlacZ, AxCAZ3-F/RGD, AxdAdB-3, and AxdAdB3-F/RGD at a MOI of 30 for 0, 1, 3, 5, and 7 days. Cell viability was evaluated using CCK-8 (Dojindo, Japan) according to the manufacturer’s protocol. Briefly, 10 μl of CCK-8 solution was added to each well and the cells were incubated for 4 h. Absorbance of the colored formazan was measured using a microplate reader at 450 nm.
The antitumor effects of AxdAdB3-F/RGD were evaluated in a subcutaneous tumor model in 6-week-old male BALB/C mice. Briefly, mice were subcutaneously injected with 5 x 106 PC3 cells for tumor xenograft formation to approximately 6–7 mm in size. The mice were then administered an intratumoral injection of AxCAZ3-F/RGD, AxdAdB-3, or AxdAdB3-F/RGD (1 x 108 plaque-forming units) once a day for three consecutive days. Tumor size was then measured weekly using an electronic caliper and tumor volume was calculated using the following formula: volume = largest dimension x smallest dimension2 x 0.4. At day 28 after treatment, the mice were sacrificed and tumor xenografts were taken and processed for immunohistochemical analysis of adenoviral hexon protein to determine adenoviral replication in tumor lesions. Briefly, paraffin-embedded sections were deparaffinized in xylene, rehydrated with ethanol, and then immunostained according to the manufacturer’s instructions using an immunohistochemical kit containing streptavidin-biotin technique (LSAB kit, Dako, Japan) and a mouse monoclonal anti-hexon antibody (#MAB805, Chemicon International).
Statistical analyses were performed using SPSS software for Windows, version 19 (SPSS Inc., Chicago, IL, USA). The data were summarized as mean ± standard deviation and the significance of differences between groups was statistically analyzed using an unpaired two-tailed t test. P < 0.05 was considered statistically significant.
CAR and integrin expression in prostate cancer cells and normal prostate epithelial cells
Flow cytometry data showed a high level of CAR expression in DU145 cells, a moderate level in LNCaP and RWPE-1 cells, and a very low level in PC3 cells (Fig 1). Integrin expression was also different in these cell lines, but the CAR-negative PC3 cell line expressed high levels of integrin αvβ5 (Fig 1).
Cells were grown and immunostained with CAR, integrin αvβ3, or αvβ5 antibody and then subjected to flow cytometric analysis. Columns, percentages of cells expressing CAR, αvβ3 and αvβ5. Data are presented as means ± standard deviation for three independent experiments.
RGD-fiber modified infection capacity of adenoviruses
After 24 h infection with adenoviruses, Western blot analysis was used to detect expression of the adenoviral hexon protein in the infected cells (Fig 2A). Hexon protein expression was similar in the CAR-positive cell lines DU145, LNCaP, and RWPE-1 after either AxCAlacZ or AxCAZ3-F/RGD infection. However, the CAR-negative PC3 cell line (expressing integrin αvβ5) showed high levels of hexon protein expression after AxCAZ3-F/RGD infection compared to cells infected with AxCAlacZ (Fig 2A), indicating that RGD-fiber modification enhanced adenovirus (AxCAZ3-F/RGD) infection capacity in CAR-negative prostate cancer cells.
A, RGD-fiber modified infection capacity of adenoviruses. Western blot analysis of hexon protein expression in mock infection (1) or infection with AxCAlacZ (2) and AxCAZ3-F/RGD (3) in prostate cancer cells. B, Flow cytometric analysis of hexon protein expression in AxCAZ3-F/RGD adenovirus-infected cells or AxCAlacZ adenovirus-infected cells. Data are presented as means ± standard deviation for three independent experiments. **P < 0.01 and N.S., not statistically significant. C, Cytopathic effects of RGD-fiber modified adenoviruses on prostate cancer cells. Cells were infected with AxCAlacZ (diamonds), AxCAZ3-F/RGD (squares), AxdAdB-3 (triangles) and AxdAdB3-F/RGD (circles) at a MOI of 30 for 0, 1, 3, 5, and 7 days and then subjected to a cell viability assay. Data are presented as means ± standard deviation for three independent experiments. **P < 0.01 and N.S., not statistically significant.
We also evaluated infectivity by fluorescence-activated cell sorting to detect the adenoviral hexon protein in infected cells (Fig 2B). CAR-positive DU145, LNCaP and RWPE-1 cells showed similar expression of hexon protein after either AxCAlacZ or AxCAZ3-F/RGD infection. In sharp contrast, the CAR-negative cell line PC3, expressing αvβ5, showed expression of hexon protein in cells infected with AxCAZ3-F/RGD but not with AxCAlacZ, which was consistent with the results of Western blot.
Cytopathic effects of adenoviruses on prostate cancer cells
AxdAdB-3 was more cytopathic in CAR-positive prostate cancer cells (LNCaP or DU145) than in CAR-negative cells (PC3). AxdAdB3-F/RGD caused potent oncolysis in both CAR-positive and CAR-negative prostate cancer cell lines (Fig 2C), indicating that RGD-fiber modified adenovirus (AxdAdB3-F/RGD) enhanced antitumor activity in CAR-negative prostrate cancer cells. However, AxdAdB3-F/RGD was not cytopathic in the HPV-immortalized normal prostate RWPE-1 epithelial cell line (Fig 2B).
Antitumor activity of AxdAdB3-F/RGD in vivo
We first established prostate cancer PC3 cell xenografts in nude mice and then directly injected AxdAdB3-F/RGD or control virus AxdAdB-3 into tumor lesions once a day for three days. The mice were sacrificed on day 28 and AxdAdB3-F/RGD antitumor activity. Tumor growth curve, and tumor volume were measured (Fig 3). Tumor xenografts were also analyzed for expression of viral hexon protein (Fig 4). Our data showed that AxdAdB3-F/RGD significantly inhibited growth of the tumor xenografts in vivo at 4 weeks after treatment compared to AxdAdB-3 (P < 0.005; Fig 3).
Prostate cancer PC3 cells were subcutaneously injected into nude mice. After tumor lesions reached approximately 6–7 mm in size virus was injected into the tumor lesion once a day for three days and the mice were sacrificed at day 28. Tumor volume was measured after animals were treated with viruses (n = 5 per group). Data are presented as mean tumor volume ± standard deviation. **P < 0.005.
AxdAdB3-F/RGD treatment resulted in more extensive tumor necrosis than AxdAdB-3 (HE staining, original magnification x 200 in top panel, x 400 in middle panel). Immunohistochemical staining of the AxdAdB3-F/RGD-treated tumors detected adenoviral hexon protein (bottom panel, original magnification x 400).
Our current study demonstrates that the RGD fiber is able to modify antitumor activity of the E1A/E1B double mutant adenovirus AxdAdB3-F/RGD in prostate cancer cells in vitro and in the nude mouse xenograft model. Our current data indicate that AxdAdB3-F/RGD possesses a potent therapeutic activity in prostate cancer. AxdAdB3-F/RGD caused strong cytopathic effects in all prostate cancer cell lines tested, regardless of CAR expression. AxdAdB3-F/RGD also inhibited growth of prostate cancer xenografts in nude mice. However, without RGD modification, AxdAdB-3 virus only showed antitumor activity in CAR-positive prostate cancer cells. Further studies are needed to evaluate the overall safety of these adenoviruses before use in human patients.
Adenoviral infection requires attachment of the virus to the surface of the targeted cells by binding of the knob domain of the fiber to CAR, and then subsequent internalization through interaction of RGD motifs of the penton base with integrin receptors αvβ3 and αvβ5.[14, 20] Thus, CAR plays a crucial role in mediating and promoting adenoviral infection. Usually, cancer cells express very low levels of CAR protein and resist adenoviral infection, and are therefore refractory to adenovirus-mediated viral therapy. In the current study, we confirmed that AxdAdB-3 infection was able to reduce viability of prostate cancer DU145 and LNCaP cell lines, which express high or moderate levels of CAR, but had limited effects of PC3 cells, which expresses very low levels of CAR. In fact, prostate cancer cell lines and tumor tissues frequently have decreased or loss of CAR expression. To enhance the infectivity of oncolytic adenovirus in CAR-negative prostate cancer, we modified the virus with RGD to produce an AxdAdB3-F/RGD virus, which significantly enhanced oncolytic adenoviral activity in prostate cancer.
AxdAdB3-F/RGD is a virus containing an RGD peptide, which can mediate not only CAR-dependent virus entry but also CAR-independent and RGD-integrin (αvβ3 and αvβ5)-dependent virus entry into targeted cells. Cancer cells expressing CAR or integrin would therefore be susceptible to AxdAdB3-F/RGD infection. Thus, although loss of or decreased CAR expression occurs frequently in prostate cancer, abundant expression of integrin αvβ3 and αvβ5 should facilitate virus infection. Our current study confirmed this hypothesis and showed that AxCAZ3-F/RGD enhanced infection capacity compared to AxCAlacZ (without RGD) in CAR-negative PC3 cells. Furthermore, AxdAdB-3 was more cytopathic in CAR-positive cells compared to CAR-negative cells; however, AxdAdB3-F/RGD caused potent cytopathic effects both in CAR-positive cells and CAR-negative cells. Also, AxdAdB3-F/RGD inhibited xenograft growth in the nude mouse model. These data suggest that RGD fiber modified adenovirus enhances adenoviral infection capacity and oncolysis efficacy through integrin (αvβ3 and αvβ5)-dependent entry. Because of its increased infection capacity, AxdAdB3-F/RGD at a lower viral dose could potentially avoid some adverse side effects while increasing the efficacy of viral therapy.
Our current data demonstrate that levels of CAR and integrin αvβ3 expression are high in DU145 and low in PC3 cells, which is similar to the findings in a previous study by Adams et. al. . Interestingly, our current study found that integrin αvβ5 expression was high in DU145 and PC3 cells. This is inconsistent with Adams’ study , which showed that integrin αvβ5 expression is high in DU145, but low in PC3 cells. However, consistent with our results, levels of integrin αvβ5 were higher than integrin αvβ3 in PC3 cells in Adams’ report.. However, the amounts of integrin αvβ5 varied. Another previous study  also demonstrated that PC3 and LNCaP cells expressed integrin αvβ5 at similar levels, which is consistent with our current results. Thus, further study is needed to verify these data and their underlying molecular mechanisms.
Furthermore, our current data demonstrate that AxdAdB3-F/RGD has fewer cytopathic effects on the HPV-immortalized normal prostate epithelial cells. Adams et. al., reported that the oncolytic adenoviral mutant AdΔΔ in prostate cancer models (AdΔΔ has a mutation of E1A in the CR-2) eliminated binding to pRb, and deletion of the 19 KD E1B enhanced the oncolytic potency. However, the published studies have shown that either E1A or E1B single mutant was able to replicate in normal cells.[24,25] Our previous study showed that E1A/ E1B double mutant oncolytic adenovirus, AxdAdB-3, did not significantly induce toxicity compared to E1A or E1B single mutant adenovirus in normal cell lines derived from the prostate. Our current study is consistent with the previous studies showing that the E1A/E1B double mutant oncolytic adenovirus was less toxic compared to E1A or E1B single mutants in normal cells but had a similar oncolytic effect in cancer cells.[19, 26] Recently, clinical trials of oncolytic adenoviruses delivered intratumorally, intraperitoneally, and intravenously to treat patients with recurrent or advanced chemotherapy refractory solid tumors was reported to be safe and potentially effective. Thus, these studies are encouraging and support the use of AxdAdB3/F-RGD as a therapeutic agent for prostate cancer. In addition, prostate cancer is well suited for oncolytic adenoviral therapy due to easy delivery of adenovirus into the intra-prostate, allowing high titers of adenovirus to infect tumor cells without dissemination to other sites. The adenovirus replication results in release of progeny viruses to infect adjacent tumor cells, leading to amplification of input virus. Again, E1A/E1B double mutant oncolytic adenovirus is able to replicate in targeted cells and lyse tumor cells that have abnormalities in p53 and/or p16/Rb/E2F pathways. Prostate cancer often has a wide range of genetic mutations, including the p53, pRb, and p16 pathways, and would be an ideal organ site for oncolytic adenovirus therapy.
Our current study provides proof-of-principle, and more work is needed before our findings can be translated into clinical application. Our current data demonstrate that E1A/E1B double-restricted oncolytic adenovirus with RGD-fiber modification enhances viral infection capacity and antitumor activity in both CAR-positive and negative prostate cancer cells in vitro and in nude mouse xenografts, while sparing normal cells.
Conceived and designed the experiments: HW. Performed the experiments: YHS. Analyzed the data: FY ZJC. Contributed reagents/materials/analysis tools: YPX AZ YS. Wrote the paper: GZ SXZ.
- 1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA: a cancer journal for clinicians. 2015;65(1):5–29. Epub 2015/01/07. doi: 10.3322/caac.21254 pmid:25559415.
- 2. Zhang L, Wu S, Guo LR, Zhao XJ. Diagnostic strategies and the incidence of prostate cancer: reasons for the low reported incidence of prostate cancer in China. Asian journal of andrology. 2009;11(1):9–13. Epub 2008/12/04. doi: 10.1038/aja.2008.21 pmid:19050685; PubMed Central PMCID: PMCPmc3735220.
- 3. Amaral TM, Macedo D, Fernandes I, Costa L. Castration-resistant prostate cancer: mechanisms, targets, and treatment. Prostate cancer. 2012;2012:327253. Epub 2012/04/25. doi: 10.1155/2012/327253 pmid:22530130; PubMed Central PMCID: PMCPmc3316959.
- 4. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. The New England journal of medicine. 2004;351(15):1502–12. Epub 2004/10/08. doi: 10.1056/NEJMoa040720 pmid:15470213.
- 5. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. The New England journal of medicine. 2012;367(13):1187–97. Epub 2012/08/17. doi: 10.1056/NEJMoa1207506 pmid:22894553.
- 6. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. The New England journal of medicine. 2011;364(21):1995–2005. Epub 2011/05/27. doi: 10.1056/NEJMoa1014618 pmid:21612468; PubMed Central PMCID: PMCPmc3471149.
- 7. Dong W, van Ginkel JW, Au KY, Alemany R, Meulenberg JJ, van Beusechem VW. ORCA-010, a novel potency-enhanced oncolytic adenovirus, exerts strong antitumor activity in preclinical models. Hum Gene Ther. 2014;25(10):897–904. Epub 2014/08/06. doi: 10.1089/hum.2013.229 pmid:25093639; PubMed Central PMCID: PMCPmc4180126.
- 8. Yang YF, Xue SY, Lu ZZ, Xiao FJ, Yin Y, Zhang QW, et al. Antitumor effects of oncolytic adenovirus armed with PSA-IZ-CD40L fusion gene against prostate cancer. Gene Ther. 2014;21(8):723–31. Epub 2014/05/23. doi: 10.1038/gt.2014.46 pmid:24849040.
- 9. Freytag SO, Stricker H, Lu M, Elshaikh M, Aref I, Pradhan D, et al. Prospective randomized phase 2 trial of intensity modulated radiation therapy with or without oncolytic adenovirus-mediated cytotoxic gene therapy in intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2014;89(2):268–76. Epub 2014/05/20. doi: 10.1016/j.ijrobp.2014.02.034 pmid:24837889; PubMed Central PMCID: PMCPmc4026796.
- 10. Satoh M, Wang H, Ishidoya S, Abe H, Moriya T, Hamada H, et al. Oncolytic virotherapy for prostate cancer by E1A, E1B mutant adenovirus. Urology. 2007;70(6):1243–8. Epub 2007/12/26. doi: 10.1016/j.urology.2007.09.031 pmid:18158069.
- 11. Douglas JT, Kim M, Sumerel LA, Carey DE, Curiel DT. Efficient oncolysis by a replicating adenovirus (ad) in vivo is critically dependent on tumor expression of primary ad receptors. Cancer Res. 2001;61(3):813–7. Epub 2001/02/28. pmid:11221860.
- 12. Rauen KA, Sudilovsky D, Le JL, Chew KL, Hann B, Weinberg V, et al. Expression of the coxsackie adenovirus receptor in normal prostate and in primary and metastatic prostate carcinoma: potential relevance to gene therapy. Cancer Res. 2002;62(13):3812–8. Epub 2002/07/05. pmid:12097294.
- 13. Reeh M, Bockhorn M, Gorgens D, Vieth M, Hoffmann T, Simon R, et al. Presence of the coxsackievirus and adenovirus receptor (CAR) in human neoplasms: a multitumour array analysis. Br J Cancer. 2013;109(7):1848–58. Epub 2013/09/12. doi: 10.1038/bjc.2013.509 pmid:24022195; PubMed Central PMCID: PMCPmc3790165.
- 14. Dehari H, Ito Y, Nakamura T, Kobune M, Sasaki K, Yonekura N, et al. Enhanced antitumor effect of RGD fiber-modified adenovirus for gene therapy of oral cancer. Cancer Gene Ther. 2003;10(1):75–85. Epub 2002/12/19. doi: 10.1038/sj.cgt.7700529 pmid:12489031.
- 15. Carroll AG, Voeller HJ, Sugars L, Gelmann EP. p53 oncogene mutations in three human prostate cancer cell lines. The Prostate. 1993;23(2):123–34. Epub 1993/01/01. pmid:8104329. doi: 10.1002/pros.2990230206
- 16. Jarrard DF, Bova GS, Ewing CM, Pin SS, Nguyen SH, Baylin SB, et al. Deletional, mutational, and methylation analyses of CDKN2 (p16/MTS1) in primary and metastatic prostate cancer. Genes Chromosomes Cancer. 1997;19(2):90–6. Epub 1997/06/01. pmid:9171999. doi: 10.1002/(sici)1098-2264(199706)19:2<90::aid-gcc4>3.3.co;2-1
- 17. Wakayama M, Abei M, Kawashima R, Seo E, Fukuda K, Ugai H, et al. E1A, E1B double-restricted adenovirus with RGD-fiber modification exhibits enhanced oncolysis for CAR-deficient biliary cancers. Clin Cancer Res. 2007;13(10):3043–50. Epub 2007/05/17. doi: 10.1158/1078-0432.ccr-06-2103 pmid:17505007.
- 18. Kanegae Y, Lee G, Sato Y, Tanaka M, Nakai M, Sakaki T, et al. Efficient gene activation in mammalian cells by using recombinant adenovirus expressing site-specific Cre recombinase. Nucleic Acids Res. 1995;23(19):3816–21. Epub 1995/10/11. pmid:7479022; PubMed Central PMCID: PMCPmc307296. doi: 10.1093/nar/23.19.3816
- 19. Fukuda K, Abei M, Ugai H, Seo E, Wakayama M, Murata T, et al. E1A, E1B double-restricted adenovirus for oncolytic gene therapy of gallbladder cancer. Cancer Res. 2003;63(15):4434–40. Epub 2003/08/09. pmid:12907616. doi: 10.1038/cgt.2008.67
- 20. Taki M, Kagawa S, Nishizaki M, Mizuguchi H, Hayakawa T, Kyo S, et al. Enhanced oncolysis by a tropism-modified telomerase-specific replication-selective adenoviral agent OBP-405 ('Telomelysin-RGD'). Oncogene. 2005;24(19):3130–40. Epub 2005/03/01. doi: 10.1038/sj.onc.1208460 pmid:15735729.
- 21. Hess K, Boger C, Behrens HM, Rocken C. Correlation between the expression of integrins in prostate cancer and clinical outcome in 1284 patients. Annals of diagnostic pathology. 2014;18(6):343–50. Epub 2014/10/13. doi: 10.1016/j.anndiagpath.2014.09.001 pmid:25305804.
- 22. Adam V, Ekblad M, Sweeney K, Müller H, Busch KH, Johnsen CT, et al. Synergistic and Selective Cancer Cell Killing Mediated by the Oncolytic Adenoviral Mutant AdΔΔ and Dietary Phytochemicals in Prostate Cancer Models. Hum Gene Ther. 2012; 23(9):1003–15. Epub 2012/08/27. doi: 10.1089/hum.2012.046 pmid:22788991.
- 23. Zheng DQ, Woodard AS, Fornaro M, Tallini G, Languino LR. Prostatic carcinomacell migration via alpha(v)beta3 integrin is modulated by a focal adhesion kinase pathway. Cancer Res. 1999;59(7):1655–64. pmid:10197643
- 24. Heise C, Hermiston T, Johnson L, Brooks G, Sampson-Johannes A, Williams A, et al. An adenovirusE1A mutant that demonstrates potent and selective systemicanti-tumoral efficacy. Nat Med. 2000;6(10): 1134–9. pmid:11017145 doi: 10.1038/80474
- 25. Harada JN, Berk AJ. p53-Independent and -dependent requirements for E1B-55K in adenovirus type 5 replication. J Virol. 1999;73(7): 5333–44. pmid:10364280.
- 26. Gomez-Manzano C, Balague C, Alemany R, Lemoine MG, Mitlianga P, Jiang H, et al. A novel E1A-E1B mutant adenovirus induces glioma regression in vivo. Oncogene. 2004;23(10):1821–8. Epub 2004/03/12. doi: 10.1038/sj.onc.1207321 pmid:15014451.
- 27. Pesonen S, Diaconu I, Cerullo V, Escutenaire S, Raki M, Kangasniemi L, et al. Integrin targeted oncolytic adenoviruses Ad5-D24-RGD and Ad5-RGD-D24-GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors. Int J Cancer. 2012;130(8):1937–47. Epub 2011/06/02. doi: 10.1002/ijc.26216 pmid:21630267.
- 28. Lee JT, Lehmann BD, Terrian DM, Chappell WH, Stivala F, Libra M, et al. Targeting prostate cancer based on signal transduction and cell cycle pathways. Cell cycle (Georgetown, Tex). 2008;7(12):1745–62. Epub 2008/07/03. pmid:18594202; PubMed Central PMCID: PMCPmc2593475. doi: 10.4161/cc.7.12.6166